Newsroom
Company news, scientific updates, events, and media coverage from across our platform and pipeline.
Events
Jun 22, 2026
Model Medicines to Present Data on Two First-in-Class Programs Ahead of Catalyst Regulatory Filings at the 2026 BIO International Convention in San Diego
Press Coverage
May 15, 2026
Fierce Biotech Profiles Model Medicines’ “Creative Models” for AI Drug Discovery
Events
May 14, 2026
Model Medicines to Present End-to-End AI Drug Discovery Platform at Fierce Biotech Week 2026 in Boston
Events
May 6, 2026
Model Medicines to Present 325-Billion-Molecule Ultra-Large Virtual Screening at 7th ACE Drug Discovery Summit in San Diego
Events
Apr 24, 2026
Model Medicines to Present at SERVC 2026: MDL-001, a Universal Direct-Acting Antiviral for Respiratory and Hepatic Viral Infections
Podcasts
Apr 22, 2026
Daniel Haders Joins The BioHub to Discuss Model Medicines’ Contrarian Approach to AI Drug Discovery
Events
Apr 17, 2026
Model Medicines to Present at ESCMID Global 2026: MDL-001, a Universal Direct-Acting Antiviral for Influenza-Like Illness and Chronic Hepatitis
Announcements
Apr 16, 2026
Model Medicines Granted First U.S. Patent related to MDL-001 in its Broad Antiviral Intellectual Property Portfolio
Press Coverage
Apr 3, 2026
New Scientist Covers MDL-001 as a Potential Multipurpose Antiviral Pill
Events
Mar 19, 2026
Model Medicines to Present Ultra-Large Virtual Screening and Agentic AI Breakthroughs at AI Convergence: Small Molecule Discovery Summit
Announcements
Mar 18, 2026
Model Medicines’ AmesNet™ Achieves Best-in-Class Performance in AI-Driven Ames Mutagenicity Prediction
Press Coverage
Mar 12, 2026
Clinical Trials Arena Highlights MDL-001’s Preclinical Potential Across Multiple Viral Infections
Press Coverage
Mar 9, 2026
GlobalData Highlights MDL-001’s Potential to Strengthen Pandemic Preparedness
Events
Mar 2, 2026
Model Medicines to Highlight Two IND-Track Assets, Record-Setting AI Platform at BIO Investment & Growth Summit 2026
Events
Feb 24, 2026
Model Medicines to Present Data on Two Drug Candidates at BIOCOM Global Partnering Conference 2026
Events
Feb 22, 2026
Model Medicines to Present Evidence of First Direct-Acting Antiviral Potent Against HCV, HBV, HDV, and Co-Infections at CROI 2026
Announcements
Feb 19, 2026
Model Medicines Demonstrates First Single-Agent Antiviral Active Against Both Hepatitis C & Hepatitis B
Events
Dec 9, 2025
Model Medicines Showcased MDL-001’s Pan-Hepatic Potential at HEP-DART 2025
Events
Dec 9, 2025
Model Medicines to Present Preclinical Data At HEPDART 2025 for HCV, HBV, and HDV, Including HCV/HBV and HDV/HBV coinfections
Announcements
Dec 4, 2025
Model Medicines Unveils Groundbreaking Preclinical Data: Oral MDL-001 Demonstrates Superiority or Equivalence to Three Standard-of-Care Antivirals: Nirmatrelvir, Remdesivir, and Sofosbuvir, Across Respiratory and Hepatic Viral Diseases
Events
Nov 10, 2025
MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety
Events
Oct 30, 2025
Model Medicines Presents at Google Cancer AI Symposium
Insights
Oct 30, 2025
Record-Scale AI Screening with Model Medicines on Google Cloud: GALILEO™ Achieves 325 Billion Molecule Throughput for Oncology Drug Discovery
Events
Oct 29, 2025
Model Medicines to Present 325 Billion Molecule Throughput Oncology Screen, at Google Cloud’s Cancer AI Symposium
Events
Oct 20, 2025
IDWeek 2025 Spotlighted MDL-001 as a “Next Tamiflu, But for Everything”
Events
Oct 20, 2025
Model Medicines To Present Preclinical Data Readout for MDL-001, a Direct-Acting, Broad-Spectrum Antiviral Targeting a Novel Viral Mechanism, at IDWeek™ 2025
Events
Oct 19, 2025
Google Cloud Highlights Model Medicines in HLTH 2025 Startup Showcase
Events
Oct 17, 2025
Google Cloud Featured Model Medicines’ 325-Billion-Molecule Breakthrough at LA Tech Week
Events
Oct 16, 2025
Model Medicines Engaged Public Market Investors Through Mizuho-Hosted NDR
Events
Aug 25, 2025
Model Medicines Selected to Present at BARDA's Enabling Technologies Showcase
Insights
Aug 14, 2025
Coronaviruses: Foundations of Broad-Spectrum Series
Insights
Aug 13, 2025
The Foundations of Broad-Spectrum Series
Events
Aug 12, 2025
Model Medicines to Present Preclinical Proof-of-Concept Data for Broad-Spectrum Antiviral MDL-001 at ID Week 2025
Announcements
Jun 13, 2025
Model Medicines Selected for BARDA VANGUARD: Building the Future of U.S. Health Security
Announcements
Jun 13, 2025
Model Medicines Named to Fierce 15
Announcements
Apr 2, 2025
Model Medicines Advances AI-Driven Drug Safety Prediction with AmesNet™, Achieving Unprecedented Accuracy and Sensitivity in Mutagenicity Testing
Podcasts
Apr 1, 2025
Model Medicines Featured on Bloomberg’s Vanguards of Health Care: Transforming Drug Discovery with AI
Events
Apr 1, 2025
Model Medicines CEO Daniel Haders II to Speak at Bloomberg's 4th Annual Generative AI Conference
Press Coverage
Mar 21, 2025
Pharma’s Almanac Named Model Medicines a Small Biotech to Watch
Preprints
Mar 20, 2025
AmesNet: A Deep Learning Model Enhancing Generalization in Ames Mutagenicity Prediction
Insights
Mar 18, 2025
Antivirals: From One Too Many to One-to-Many
Insights
Mar 11, 2025
Biotech’s Undead: Zombies and Vampires
Insights
Mar 4, 2025
Transforming Pandemic Preparedness: AI-Driven Predictive Tools and Next-Generation Broad-Spectrum Antivirals
Insights
Feb 25, 2025
The Future of Drug Discovery: 2025 as the Inflection Year for Hybrid AI and Quantum Computing
Insights
Feb 19, 2025
The STAT News Report: A Wake-Up Call for AI Drug Discovery
Events
Feb 11, 2025
Model Medicines CEO Daniel Haders Delivers Keynote on the Future of AI Drug Discovery
Press Coverage
Feb 4, 2025
Model Medicines Gains Industry Recognition for AI-Driven Antiviral Breakthroughs
Announcements
Jan 28, 2025
Model Medicines Unveils Generative AI, Multi-Modal Therapeutic Pipeline Breakthrough, Demonstrating End-To-End Drug Discovery Capabilities
Press Coverage
Jan 27, 2025
Model Medicines Named Among Top AI Drug Development Startups to Watch in 2025
Preprints
Jan 26, 2025
Demonstrating End-to-End Drug Discovery: GALILEO™ Unlocks Generative AI for Chemistry
Announcements
Jan 21, 2025
Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral
Preprints
Jan 14, 2025
MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases
Events
Dec 3, 2024
Model Medicines to Keynote CPHI Middle East
Press Coverage
Nov 29, 2024
Model Medicines Makes GEN's List of Top AI Drug Discovery Companies to Watch
Papers
Sep 10, 2024
AI Hit Rates and Novelty
Press Coverage
Sep 3, 2024
BioTuesdays Features Model Medicines’ AI-Driven Approach to Drug Discovery
Announcements
Jun 5, 2024
Model Medicines Announces Nomination of Preclinical Candidate, MDL-4101, Targeting BRD4 for the Treatment of Thyroid Cancer
Announcements
Apr 24, 2024
Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor
Insights
Apr 23, 2024
The AIDD Code
Events
Apr 17, 2024
Model Medicines to Participate in Upcoming TSX Investor Event
Announcements
Apr 9, 2024
Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers
Preprints
Apr 8, 2024
Model Medicines Reveals Breakthrough AI Discovery: RdRp Thumb-1, A Universal RNA Antiviral Target, and MDL-001, a Potent Inhibitor
Preprints
Mar 28, 2024
Model Medicines Publishes Groundbreaking Preprint on AI-Driven Drug Discovery
Announcements
Mar 20, 2024
Model Medicines Discovers New Pan-Antiviral Chemical Entity (NCE) Library, Achieving Unprecedented 66.7% Hit Rate Using Proprietary AI Platform
Events
Mar 11, 2024
20th BioPharma Drug Discovery Nexus Conference
Papers
Mar 11, 2024
Dissimilar, Drug-Like, Novel Chemical Entities (DDL-NCEs); Using Multimodal Generative AI
Papers
Dec 19, 2023
Biochemistry's Hidden Matrix: Atomic Constellations
Events
Nov 13, 2023
Advancing Preparedness Through BARDA Industry Day
Events
Nov 9, 2023
JPM CBRN Medical TechWatch
Events
Oct 12, 2023
Precision in Drug Discovery & Preclinical Summit 2023
Papers
Sep 27, 2023
Vanity Metrics & Black Boxes ≠Therapeutics
Events
Sep 14, 2023
BARDA - TechWatch Meeting
Papers
Sep 12, 2023
Breaking the Data Dogma
Events
May 3, 2023
TiEcon 2023 Recap
Events
Apr 27, 2023
Model Medicines Download Day
Papers
Mar 20, 2023
Overcoming PAINS in AI Drug Discovery
Insights
Feb 13, 2023
Cryo-EM at the Forefront of AI Drug Discovery: Exploring Deep Chemical Space
Papers
Dec 13, 2022
The Tripledemic: AI-Drug Discovery and the Quest for a Pan-Antiviral Drug
Insights
Nov 23, 2022
8VC’s David Moskowitz on Investing in the Future of AI-Driven Drug Discovery
Events
Nov 15, 2022
Model Medicines Selected to Participate at the 5th Annual Evercore ISI HealthCONx Conference
Events
Nov 2, 2022
Model Medicines Presented to Investors at Wells Fargo’s Private Biotech Symposium
Press Coverage
Oct 6, 2022
BioWorld Spotlights Model Medicines’ Expansion Into High-Value Oncology Targets
Events
Oct 4, 2022
Model Medicines Selected to Participate at the 2022 BMO Healthcare Conference
Announcements
Oct 4, 2022
Model Medicines Announces Launch of Oncology Programs with Multiple AI-Discovered Compounds Demonstrating Drug-Like Activity for Two High Value, Difficult to Drug, Oncogenic and Epigenetic Targets
Events
Sep 28, 2022
Model Medicines Advanced MDL-001 Toward FDA Engagement Ahead of BioPharm America
Press Coverage
Mar 28, 2022
Model Medicines Featured in C&EN's Coverage of Next-Generation COVID-19 Antivirals
Events
Mar 1, 2022
Model Medicines’ MDL-001 Advanced Into the Spotlight at Truist’s Life Sciences AI Symposium
Insights
Aug 3, 2021
Model Medicines and Sumit Chanda Explore the Future of Broad-Spectrum Antivirals
Press Coverage
Jul 1, 2020
The San Diego Union-Tribune Spotlights the Early Vision Behind Model Medicines
Announcements
Apr 6, 2020
Model Medicines Accepted to Join The Alliance for Artificial Intelligence in Healthcare (AAIH)
Press Coverage
Mar 30, 2020
Model Medicines COVID-19 Drug Development Program Highlighted by Catalyst Health 2.0
Press Coverage
Mar 29, 2020
Model Medicines Highlighted as VC Backed StartUp Battling COVID-19 by MedCityNews
Press Coverage
Mar 28, 2020
Model Medicines COVID-19 Drug Development Program Highlighted by FreshBrewedTech
Announcements
Mar 25, 2020
Model Medicines Joins The Fight To Battle The Global COVID-19 Pandemic
Events
Jan 16, 2020